Immunome, Inc. (NASDAQ:IMNM) Receives Consensus Recommendation of “Buy” from Analysts

Immunome, Inc. (NASDAQ:IMNM) has been given a consensus recommendation of “Buy” by the six ratings firms that are currently covering the firm, MarketBeat.com reports. Six equities research analysts have rated the stock with a buy recommendation. The average 12 month target price among brokers that have issued a report on the stock in the last year is $29.00.

IMNM has been the subject of a number of recent research reports. Wedbush reaffirmed an “outperform” rating and issued a $33.00 target price on shares of Immunome in a research note on Tuesday, August 13th. Piper Sandler dropped their price objective on shares of Immunome from $27.00 to $23.00 and set an “overweight” rating for the company in a report on Tuesday, August 13th.

Immunome Trading Up 0.6 %

IMNM stock opened at $15.50 on Thursday. The firm has a 50-day moving average of $14.40 and a two-hundred day moving average of $16.25. Immunome has a 12 month low of $6.65 and a 12 month high of $30.96. The company has a market cap of $929.52 million, a price-to-earnings ratio of -2.05 and a beta of 1.77.

Immunome (NASDAQ:IMNM) last posted its quarterly earnings results on Monday, August 12th. The company reported ($0.49) EPS for the quarter, missing the consensus estimate of ($0.38) by ($0.11). Immunome had a negative net margin of 2,435.02% and a negative return on equity of 38.19%. The company had revenue of $2.36 million during the quarter, compared to analyst estimates of $2.62 million. As a group, equities analysts forecast that Immunome will post -1.92 earnings per share for the current year.

Insider Transactions at Immunome

In related news, Director Jean Jacques Bienaime bought 7,000 shares of the firm’s stock in a transaction on Friday, August 16th. The shares were bought at an average price of $13.94 per share, with a total value of $97,580.00. Following the completion of the transaction, the director now directly owns 16,615 shares of the company’s stock, valued at approximately $231,613.10. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. In related news, insider Jack Higgins sold 3,524 shares of the stock in a transaction that occurred on Thursday, August 15th. The shares were sold at an average price of $13.93, for a total transaction of $49,089.32. Following the completion of the transaction, the insider now owns 16,000 shares of the company’s stock, valued at approximately $222,880. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Jean Jacques Bienaime bought 7,000 shares of the company’s stock in a transaction that occurred on Friday, August 16th. The stock was bought at an average price of $13.94 per share, with a total value of $97,580.00. Following the acquisition, the director now directly owns 16,615 shares in the company, valued at approximately $231,613.10. The disclosure for this purchase can be found here. Company insiders own 8.60% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently modified their holdings of the company. Avidity Partners Management LP acquired a new position in Immunome during the 4th quarter worth about $14,268,000. Mayo Clinic purchased a new position in shares of Immunome in the fourth quarter valued at approximately $1,161,000. Lord Abbett & CO. LLC acquired a new position in shares of Immunome in the first quarter valued at approximately $10,994,000. Swiss National Bank acquired a new position in shares of Immunome in the first quarter valued at approximately $1,762,000. Finally, Cetera Investment Advisers purchased a new stake in Immunome during the 1st quarter worth approximately $3,038,000. 44.58% of the stock is currently owned by hedge funds and other institutional investors.

About Immunome

Immunome, Inc, a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate.